|
|
Article: Company sees positive results for indiplon in adults with transient insomnia.
- Article from:
- Clinical Trials Week
- Article date:
- April 5, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 APR 5 - (NewsRx.com & NewsRx.net) -- Neurocrine Biosciences, Inc., (NBIX) announced positive results from its phase III trial with the modified release formulation of indiplon, achieving highly statistically significant results in adults with transient insomnia.
The study was a randomized, double-blind, placebo-controlled, parallel-group, multicenter sleep laboratory phase III clinical trial.
The primary objective of the study was to assess the efficacy of two dose levels of indiplon modified release (20 mg and 30 mg) relative to placebo on sleep initiation in 325 healthy adult subjects. The primary endpoint for the study was Latency to Persistent ...